Table 1.
Pol β mRNA expression and breast cancer (METABRIC cohort, n = 1952).
| Variable | POLBmRNA expression | X2 p value | |
|---|---|---|---|
| Low N (%) | High N (%) | ||
| A) Pathological parameters | |||
| Lymph node stage | |||
| Negative | 90 (44.5%) | 922 (53%) | 0.023a |
| Positive | 112 (55.5%) | 822 (47%) | 0.039a |
| Grade b | |||
| G1 | 7 (3.6%) | 156 (9.2%) | 0.01a |
| G2 | 67 (34.2%) | 698 (41.5%) | 0.059 |
| G3 | 122 (62.2%) | 829 (49.3%) | 0.001a |
| Mitotic index | |||
| M1 (low; mitoses < 10) | 92 (54.5%) | 909 (62%) | 0.07 |
| M2 (medium; mitoses 10–18) | 41 (24.2%) | 337 (23%) | 0.852 |
| M3 (high; mitosis >18) | 36 (21.3%) | 220 (15%) | 0.05 |
| Pleomorphism | |||
| 1 (Small‐regular uniform) | 1 (0.6%) | 16 (1%) | 1.0 |
| 2 (Moderate variation) | 47 (27.8%) | 549 (37.4%) | 0.017a |
| 3 (Marked variation) | 121 (71.6%) | 902 (61.4%) | 0.044a |
| Tubule formation | |||
| 1 (>75% of definite tubule) | 5 (3%) | 52 (3.5%) | 0.84 |
| 2 (10%–75% definite tubule) | 35 (20.7%) | 319 (21.7%) | 0.77 |
| 3 (<10% definite tubule) | 129 (76.3%) | 1096 (74.7%) | 0.941 |
| Triple negative | |||
| (No) | 141 (69.1%) | 1498 (85.7%) | 1.8 × 10−9a |
| (Yes) | 63 (30.9%) | 250 (14.3%) | 1.8 × 10−9a |
| Basal like | |||
| (No) | 39 (19.1%) | 1653 (94.6%) | 7.6 × 10−13a |
| (Yes) | 165 (80.9%) | 95 (5.4%) | 7.6 × 10−13a |
| ER | |||
| (Negative) | 82 (41%) | 355 (20.6%) | 2.0 × 10−10a |
| (Positive) | 118 (59%) | 1367 (79.3%) | 1.9 × 10−10a |
| Genefu subtype | |||
| ER−/Her‐2 negative | 63 (35%) | 236 (15.0%) | 1.3 × 10−10a |
| ER+/Her‐2 negative/high proliferation | 45 (25%) | 584 (37.5%) | 0.001a |
| ER+/Her‐2 negative/low proliferation | 39 (19.5%) | 587 (37.5%) | 3.9 × 10−5a |
| Her‐2 positive | 33 (16.5%) | 156 (10%) | 0.001a |
| PAM50 subtype | |||
| PAM50.Her2 | 47 (26.4%) | 191 (12%) | 1.0 × 10−6a |
| PAM50.Basal | 57 (32.2%) | 265 (16.7%) | 5.2 × 10−6a |
| PAM50.LumA | 39 (21.9%) | 675 (42.7%) | 6.8 × 10−8a |
| PAM50.LumB | 35 (19.7%) | 449 (28.4%) | 0.0097 |
HER2: human epidermal growth factor receptor 2; ER: oestrogen receptor; PgR: progesterone receptor; CK: cytokeratin; Basal‐like: ER−, HER2 and positive expression of either CK5/6, CK14 or EGFR; Triple negative: ER−/PgR‐/HER2‐.
a
Statistically significant.
b
Grade as defined by NGS.